Efficacy and Safety of BeEAM, a Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphoma.
10.19746/j.cnki.issn.1009-2137.2025.01.036
- Author:
Feng-Quan GOU
1
;
Jia-Jia LI
1
;
Jun-Feng ZHU
1
;
Kai ZHU
1
;
Li-Li HAN
1
;
Meng WANG
1
;
Feng ZHANG
1
Author Information
1. Department of Hematology, The First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, Anhui Province ,China.
- Publication Type:Journal Article
- Keywords:
malignant lymphoma;
autologous stem cell transplantation;
BeEAM regimen;
therapeutic effect
- MeSH:
Humans;
Transplantation Conditioning/methods*;
Transplantation, Autologous;
Hematopoietic Stem Cell Transplantation;
Lymphoma/therapy*;
Cytarabine/therapeutic use*;
Female;
Male;
Melphalan/therapeutic use*;
Adult;
Middle Aged;
Bendamustine Hydrochloride/therapeutic use*
- From:
Journal of Experimental Hematology
2025;33(1):241-245
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the efficacy and safety of the conditioning regimen BeEAM (bendamustine+et-oposide+cytarabine+melphalan) in autologous stem cell transplantation (ASCT) for patients with malignant lymphoma.
METHODS:The clinical data of 20 patients with malignant lymphoma who underwent ASCT after conditioning with BeEAM regimen from January 2021 to December 2022 in the First Affiliated Hospital of Bengbu Medical University were collected, and the clinical characteristics before transplantation, conditioning-related toxicity, hematopoietic reconstitution after transplantation, and therapeutic effects were analyzed. 67 patients with malignant lymphoma who did not undergo ASCT during the same period were selected as the control group, and the 1-year progression-free survival (PFS) rate and overall-survival (OS) rate between the ASCT group and the non-ASCT group were compared.
RESULTS:15 cases achieved complete remission (CR) and 5 cases achieved partial remission (PR) before transplantation in ASCT group. During the conditioning process of patients in the ASCT group, 14 cases experienced gastrointestinal adverse reactions, 13 cases experienced neutropenic fever, 10 cases experienced oral mucositis, 2 cases experienced abnormal liver function, and only 1 case experienced acute renal injury. All the adverse reactions resolved after symptomatic treatment. After transplantation, 19 cases achieved hematopoietic reconstitution, and only one case had poor platelet engraftment. The median time of peripheral white blood cell (WBC) engraftment was 9 (9-16) days, and the median time of platelet engraftment was 12 (10-23) days. By the end of follow-up, there were no transplant-related deaths. The 1-year PFS rates in the ASCT group and the non-ASCT group were 94.4% and 68.5%, respectively; The 1-year OS rates were 94.4% and 83.5%, respectively. The median PFS and OS time for both groups were not reached. The PFS in the ASCT group was significantly better than that in the non-ASCT group (P < 0.05), and there was no significant difference in OS between the two groups ( P >0.05).
CONCLUSION:BeEAM regimen is safe and effective as a conditioning treatment for ASCT in patients with malignant lymphoma, with tolerable adverse reactions, controllable non-hematological toxicity, smooth hematopoietic reconstitution, and considerable short-term efficacy. However, further follow-up is required to evaluate its long-term efficacy.
